Renaissance Technologies LLC Has $1.27 Million Position in Spero Therapeutics, Inc. (NASDAQ:SPRO)

Renaissance Technologies LLC boosted its position in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 14.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 975,952 shares of the company’s stock after acquiring an additional 121,492 shares during the quarter. Renaissance Technologies LLC owned 1.81% of Spero Therapeutics worth $1,269,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in SPRO. Virtu Financial LLC bought a new stake in shares of Spero Therapeutics during the 1st quarter valued at approximately $31,000. Acadian Asset Management LLC boosted its stake in shares of Spero Therapeutics by 121.8% in the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock valued at $1,310,000 after purchasing an additional 418,742 shares during the last quarter. Murchinson Ltd. grew its holdings in Spero Therapeutics by 1.3% during the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after acquiring an additional 11,210 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of Spero Therapeutics in the 4th quarter valued at $1,570,000. Finally, Vanguard Group Inc. raised its holdings in shares of Spero Therapeutics by 0.6% during the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock valued at $2,844,000 after purchasing an additional 9,675 shares during the period. 25.60% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SPRO has been the topic of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a report on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Spero Therapeutics in a research report on Thursday. Finally, TD Cowen upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th.

Spero Therapeutics Stock Performance

SPRO opened at $1.30 on Friday. Spero Therapeutics, Inc. has a fifty-two week low of $0.99 and a fifty-two week high of $1.89. The firm has a 50-day moving average of $1.32 and a 200 day moving average of $1.44. The firm has a market cap of $70.19 million, a P/E ratio of 3.02 and a beta of 0.62.

Spero Therapeutics (NASDAQ:SPRO) last released its earnings results on Monday, August 5th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. Spero Therapeutics had a net margin of 14.74% and a return on equity of 25.67%. The firm had revenue of $10.20 million during the quarter, compared to the consensus estimate of $9.80 million. During the same period in the prior year, the firm earned ($0.23) EPS. Equities research analysts predict that Spero Therapeutics, Inc. will post -1.59 earnings per share for the current fiscal year.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.